| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Pediatrics (Dr. Andrews) and Medicine (Drs. Massey and Sanders), Duke University Medical Center, Durham, and the Department of Neurology (Dr. Howard), University of North Carolina at Chapel Hill, Chapel Hill, NC.
We assessed the influence of race, sex, and puberty upon clinical features and outcome in 115 patients with autoimmune juvenile myasthenia gravis (JMG). These demographic variables influenced not only disease incidence but also disease severity, response to therapy, and outcome, despite comparable therapeutic strategies. Among white patients, those with prepubertal onset had low incidence and equal sex ratio; the incidence in females increased during and after puberty; males had lesser disease severity than females during and after puberty (p < 0.05); spontaneous remissions were most frequent (44%, p = 0.001) and persistence of active JMG for more than 10 years was least frequent (p = 0.05) in patients with prepubertal onset; remissions were more frequent after early than late thymectomy (p = 0.03); and final disease severity was less after early than late thymectomy. Black patients had similar incidence, disease severity, and sex ratio (F:M = 2:1) with pre-, peri-, or postpubertal disease onset; infrequent spontaneous or treatment-induced remissions; and the same final disease severity after early or late thymectomy. These observations imply that race and sex hormones modify the clinical features and outcome of JMG; spontaneous remissions are common in white patients with prepubertal disease onset; early thymectomy may be more beneficial than late thymectomy in white patients; and the role of thymectomy in the youngest patients is uncertain. We suggest that demographic factors should be considered when evaluating past and future therapeutic strategies for JMG.
Address correspondence and reprint requests to Dr. P. Ian Andrews, Division of Pediatric Neurology, Box 3533, Duke University Medical Center, Durham, NC 27710.
Received October 19, 1993. Accepted in final form January 20, 1994.
This article has been cited by other articles:
|
|
 |
|
  M. Essa, Y. El-Medany, W. Hajjar, Z. Hariri, F. Al-Mulhim, M. Salih, M. Ashour, and K. Al-Kattan Maximal thymectomy in children with myasthenia gravis Eur. J. Cardiothorac. Surg., August 1, 2003; 24(2): 187 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Haliloglu, B. Anlar, S. Aysun, M. Topcu, H. Topaloglu, G. Turanli, and D. Yalnizoglu Gender Prevalence in Childhood Multiple Sclerosis and Myasthenia Gravis J Child Neurol, May 1, 2002; 17(5): 390 - 392. [Abstract] [PDF]
|
|
|
|
|
|
H. K. Kolski, P. C.W. Kim, and J. Vajsar Video-Assisted Thoracoscopic Thymectomy in Juvenile Myasthenia Gravis J Child Neurol, August 1, 2001; 16(8): 569 - 573. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Jaretzki III, R. J. Barohn, R. M. Ernstoff, H. J. Kaminski, J. C. Keesey, A. S. Penn, and D. B. Sanders Myasthenia gravis: Recommendations for clinical research standards Neurology, July 12, 2000; 55(1): 16 - 23. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jaretzki III, R. J. Barohn, R. M. Ernstoff, H. J. Kaminski, J. C. Keesey, A. S. Penn, and D. B. Sanders Myasthenia gravis: recommendations for clinical research standards Ann. Thorac. Surg., July 1, 2000; 70(1): 327 - 334. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Janas and R. J. Barohn A Clinical Approach to the Congenital Myasthenic Syndromes J Child Neurol, March 1, 1995; 10(2): 168 - 169. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
